Skip to content

Inhaled Fluticasone in Wheezy Infants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN86717853
Enrollment
200
Registered
2005-11-28
Start date
1997-05-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in children Respiratory Asthma

Interventions

Low dose inhaled corticosteroids (fluticasone propionate) versus placebo

Sponsors

Wythenshawe Hospital (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children aged 6 months to 4 years 2. Two episodes of doctor verified wheeze or one episode continuous for more than 4 weeks

Exclusion criteria

Exclusion criteria: 1. Pre-term less than 34 weeks gestation 2. Neonatal lung disease or other lung disease 3. Other chronic disease 4. Children already or previously used an inhaled corticosteroid 5. Children who cannot use the spacer device

Design outcomes

Primary

MeasureTime frame
1. Occurrence of asthma at age 5 and 6 2. Lung function at age 5 3. Non-specific bronchial hyper-reactivity at age 5 4. Number of courses and total dose of add-on fluticasone propionate required

Secondary

MeasureTime frame
1. Rescue and added asthma medication 2. Number of exacerbations 3. Safety parameters ? length/height, weight 4. Symptom scores 5. Adrenal function

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 11, 2026